ReviewFrontiers in pharmacology2026
Plant metabolites: potential treatments for ischemic acute kidney injury.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia-reperfusion injury is a leading cause of acute kidney injury (AKI), which is characterized by high morbidity and mortality, as well as a substantial risk of progression to chronic kidney disease (CKD). Although supportive care has improved considerably, effective disease-modifying therapies are still lacking. Therefore, the development of new therapeutic drugs for ischemic AKI is crucial. Active metabolites derived from medicinal plants, owing to their low toxicity and multi-target characteristics, are promising candidates for ischemic AKI therapy. This study reviews the pathogenesis of ischemic AKI from multiple dimensions, including metabolic disturbances, oxidative stress, inflammation, endoplasmic reticulum stress, mitochondrial dysfunction, and several forms of regulated cell death (e.g., ferroptosis, apoptosis, pyroptosis). It also summarizes plant metabolites (polyphenols, phenylpropanoids, terpenoids, saponins, alkaloids, and extracts) that can ameliorate ischemic AKI by targeting the aforementioned mechanisms. These metabolites exert their protective effects by modulating key signaling pathways (e.g., Nrf2/HO-1, NF-κB, PI3K/Akt). However, further mechanistic studies, standardization, and well-designed clinical trials are essential for their use and to ensure their integration into clinical practice as effective therapeutic options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.